
Septerna Inc (SEPN) Stock Forecast & Price Target
Septerna Inc (SEPN) Analyst Ratings
Bulls say
Septerna is facing increased risks in running a CSU study without further clarity, but their decision to wait on Ph2b initiation may enable capital-efficient exploration of SEP-631 in a smaller signal-finding study. Their enthusiasm for their oral PTH asset and Native GPCR platform is increased due to physician interest in novel PTH treatments, leading to a potential for significant market share for their asset SEP-479. With conservative assumptions and a discounted cash flow valuation, Septerna's price objective is estimated to be $40/shr with a 30% probability of approval for their lead MRGPRX2 receptor agonist candidate and 15% probability of approval for their TSHR NAM and GLP-1R/GIPR/GCGR agonist candidates.
Bears say
Septerna is facing substantial risks in its drug discovery and pipeline development, with a low probability of success for its oral native platform and a weak forecast for future revenue and earnings due to competition in multiple therapeutic areas. Recent competitor failures have limited direct read-through, but the company's current strategy and focus on targeting mast cell-driven diseases may not be sufficient for overall success in the market. Despite a strong financial position, with over $500M in cash and securities, the company's ongoing net losses and lack of significant service revenue suggest that investments should be made cautiously.
This aggregate rating is based on analysts' research of Septerna Inc and is not a guaranteed prediction by Public.com or investment advice.
Septerna Inc (SEPN) Analyst Forecast & Price Prediction
Start investing in Septerna Inc (SEPN)
Order type
Buy in
Order amount
Est. shares
0 shares